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Introduction: Rovalpituzumab tesirine (Rova-T) is an
antibody-drug conjugate targeting DLL3, an atypical Notch
ligand expressed in SCLC tumors. We evaluated the efficacy
of Rova-T versus placebo as maintenance therapy in pa-
tients with extensive-stage–SCLC after platinum-based
chemotherapy.
Methods: MERU was a phase 3 randomized, double-
blinded, placebo-controlled study. Patients without disease
progression after four cycles of platinum-based, front-line
chemotherapy were randomized in a 1:1 ratio to receive 0.3
mg/kg Rova-T or placebo (every 6 wk, omitted every third
cycle). Primary efficacy end points were progression-free
survival (PFS) evaluated by the Central Radiographic
Assessment Committee and overall survival (OS) in patients
with DLL3-high tumors.
Results:Median age of all randomized patients (N ¼ 748)
was 64 years; 78% had TNM stage IV disease. At futility
analysis of the subset with DLL3-high tumors, the
hazard ratio for OS was 1.07 (95% confidence interval:
0.84–1.36) favoring the placebo arm, with median OS
of 8.5 and 9.8 months in the Rova-T and placebo arms,
respectively; futility criteria were met. Rova-T signifi-
cantly improved PFS versus placebo by investigator
assessment (4.0 versus 1.4 mo, hazard ratio ¼ 0.48,
p < 0.001). Any-grade adverse events (20%) in the
Rova-T arm were pleural effusion (27%), decreased
appetite (27%), peripheral edema (26%), photosensi-
tivity reaction (25%), fatigue (25%), nausea (22%),
and dyspnea (21%).
Conclusions: Because of the lack of survival benefit in the
Rova-T arm, the study did not meet its primary end point
and was terminated early. As a result, the Central Radio-
graphic Assessment Committee evaluation of PFS was not
performed. The frequency of grade greater than or equal to
3 and drug-related toxicities were higher with Rova-T
versus placebo. Rova-T was associated with unique toxic-
ities, such as pleural and pericardial effusions, photosensi-
tivity reaction, and peripheral edema, which should be
carefully considered in the population with extensive-stage–
SCLC. 2021 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Rovalpituzumab tesirine; Small cell lung cancer;
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Platinum-based systemic chemotherapy (carboplatin
or cisplatin combined with etoposide) is the mainstay of
front-line treatment in extensive-stage–SCLC (ES-SCLC),
with initial response rates of 60% to 80% including
complete response (CR) rates of 15% to 20%. However,
responses are not durable, and relapse is common.1,2
Several recent trials have revealed moderate improve-
ments in survival when immune checkpoint inhibitors
are combined with first-line chemotherapy, leading to
the regulatory approval of anti-programmed death-
ligand 1 antibodies, atezolizumab and durvalumab, for
first-line treatment of ES-SCLC.3,4 Despite these ad-
vancements, median overall survival (OS) with atezoli-
zumab and durvalumab combined with chemotherapy
remains limited (12 mo and 13 mo, respectively).3,4
Thus, ES-SCLC remains a rapidly progressing disease
with poor prognosis.
DLL3 is an atypical ligand of the Notch receptor
family identified as a novel therapeutic target in SCLC
and other high-grade neuroendocrine carcinomas.
DLL3 is expressed during embryonic development, in
which one of its roles is in formation of axial skeleton,
and a rare autosomal recessive genetic disorder,
spondylocostal dysostosis type 1, is caused by muta-
tions in the DLL3 gene.5 There is no detectable
DLL3 protein expression in normal adult tissues;
however, it is expressed in most SCLC and large-cell
neuroendocrine carcinoma tumors.6,7 Tumor DLL3
expression seems to remain unchanged pre- and post-
chemotherapy, suggesting analysis of diagnostic
1572 Johnson et al Journal of Thoracic Oncology Vol. 16 No. 9archival tissue is adequate to estimate posttreatment
DLL3 expression level.8
Rovalpituzumab tesirine (Rova-T) is a first-in-class
antibody-drug conjugate composed of a DLL3-targeting
immunoglobulin G1 monoclonal antibody tethered to a
toxic DNA crosslinking agent of pyrrolobenzodiazepine
(PBD) class by means of a protease-cleavable linker.6,9 In
the first-in-human, phase 1 study of Rova-T in patients
with ES-SCLC progressing on greater than or equal to 1
previous regimens, the objective response rate (ORR) as
evaluated by an Independent Review Committee was
16% and the disease control rate was 64%, with better
efficacy outcomes in patients with DLL3-high tumors
(detectable DLL3 expression in 50% of tumor cells
staining positive using a mouse anti-DLL3 antibody)
versus those with DLL3-low tumors (detectable DLL3
expression in <50% of tumor cells).9 Activity of Rova-T
observed in phase 1 in patients with relapsed or re-
fractory tumors, although difficult to interpret defini-
tively owing to the small number of patients and the
single-arm study design, seemed sufficiently promising
to prompt initiation of several studies in ES-SCLC. These
included a phase 2 single-arm study (TRINITY) in third
and later lines of therapy and two randomized phase 3
studies, TAHOE (Rova-T versus topotecan in second-line
ES-SCLC) and the MERU study described here. In the
TRINITY study, Rova-T yielded an ORR (as evaluated by
central radiographic assessment) of 12.4% and a disease
control rate of 70%. For patients with DLL3-high tumors
(defined in this study as 75% DLL3-positive tumor
cells using a rabbit anti-DLL3 antibody), the ORR was
14.3%, whereas patients with DLL3-positive tumors
(defined as 25% DLL3-positive tumor cells) had an
ORR of 13.2%.10
When compared with standard-of-care platinum-
based chemotherapy, Rova-T was found to substantially
reduce the frequency of tumor-initiating cells in low-
passage SCLC patient-derived xenografts.6 By targeting
this resistant, residual cell population, Rova-T has a
compelling rationale for use in the postinduction chemo-
therapy maintenance setting. We hypothesized that the
preclinical and clinical activities observed in patients with
recurrent or relapsed SCLC would also be evident among
patients with ES-SCLC who would be treated with Rova-T
in the maintenance setting.11,12 To this end, we evaluated
whether Rova-T improves progression-free survival (PFS)
and OS compared with placebo in patients with ES-SCLC
after platinum chemotherapy.Materials and Methods
Study Design
MERU was a phase 3 randomized, double-blinded,
placebo-controlled study enrolling patients withES-SCLC who have stable disease, partial response (PR),
or CR after four cycles of first-line platinum-based
chemotherapy. On completion of chemotherapy and
before randomization, eligible patients were offered
prophylactic cranial irradiation (PCI), if in accordance
with local guidelines.
The primary end points were PFS determined by a
Central Radiographic Assessment Committee (CRAC) per
Response Evaluation Criteria in Solid Tumors version 1.1
(RECIST v.1.1) and OS in the population with DLL3-high
tumors. The secondary end points included PFS (evalu-
ated by CRAC) and OS in all randomized patients and
change in patient-reported outcome with physical func-
tioning as measured by the European Organization for
Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30) in randomized pa-
tients. Exploratory end points in both DLL3-high and
randomized patients included PFS by investigator, ORR
and clinical benefit rate (CBR) per CRAC and investigator
(on the basis of RECIST v.1.1), and duration of response
(DOR) per CRAC and investigator.
The study was approved by local institutional review
boards of all participating centers, and all patients pro-
vided written informed consent. The study was designed
according to Good Clinical Practice Guidelines and the
Declaration of Helsinki. The trial is registered at www.
clinicaltrials.gov (NCT03033511).Randomization and Study Treatment
Patients were randomized in a 1:1 ratio to receive 0.3
mg/kg intravenous Rova-T or intravenous placebo on
day 1 of each 6-week cycle, omitting every third cycle.
Premedication and postmedication included 8 mg orally
of dexamethasone or placebo twice daily on the day
before, day of, and day after study drug administration.
Randomization was stratified by postchemotherapy
response (stable disease versus PR or CR) according to
the RECIST v.1.1 criteria,13 DLL3 expression (performed
in a designated central IHC laboratory using Ventana
DLL3 [SP347] assay (Ventana Medical Systems, Inc -
Roche Diagnostics, Oro Valley, AZ); <75% defined as
DLL3-low versus 75% defined as DLL3-high), history
of central nervous system (CNS) metastases (yes versus
no), and PCI versus no PCI for patients with no history of
CNS metastases.Patients
Eligible patients were aged greater than or equal to
18 years with histologically or cytologically confirmed
ES-SCLC who had completed four cycles of front-line
platinum-based chemotherapy (cisplatin or carboplatin
with etoposide or irinotecan) at least 3 weeks but not
more than 9 weeks before randomization and had stable
September 2021 Rova-T Maintenance Therapy for ES-SCLC 1573disease, PR, or CR per RECIST v.1.1, as evaluated by the
investigator. ES disease was defined, on the basis of the
Veterans Administration Lung Study Group staging, as
SCLC with disease involvement of any anatomical loca-
tion exceeding that of limited-stage disease (disease
confined to the hemithorax of origin, with or without the
involvement of regional lymph nodes, including ipsilat-
eral and contralateral hilar, ipsilateral, and contralateral
mediastinal and ipsilateral supraclavicular nodes).14 All
patients had representative tumor tissue available for
central assessment of DLL3 expression. Patients with a
history of CNS metastases were required to complete
definitive local treatment and to have stable or improved
CNS disease status on the basis of brain imaging within
28 days before randomization, off or on a stable dose of
corticosteroids.
Main exclusion criteria were as follows: any previous
systemic chemotherapy or targeted therapy for SCLC other
than platinum-based front-line therapy; any previous
disease-directed radiotherapy except PCI, palliative radio-
therapy to a nonprogressing lesion, or preplanned radio-
therapy for nonprogressing CNSmetastases present before
start of first-line therapy; documented history of a cerebral
vascular event, unstable angina, myocardial infarction, or
cardiac symptoms consistent with New York Heart Asso-
ciation classes III to IV within 6 months before first dose of
study therapy; documented capillary leak syndrome; grade
greater than or equal to 2 pleural or pericardial effusion
within four weeks of randomization or previous history
requiring pericardiocentesis or thoracentesis; and previous
exposure to a PBD-based drug.
Study Assessments and Statistical Methods
The study was designed with dual primary end
points—PFS as evaluated by the blinded CRAC and OS
in the population with DLL3-high tumors. The sample
size was primarily determined on the basis of OS
analysis. Considering the study population and the
study hypothesis on Rova-T efficacy, the median OS in
the placebo and Rova-T arms was expected to be
approximately 9 months11,12 and 13 months, respec-
tively. Such an increase in median OS in the Rova-T
arm corresponds to a hazard ratio (HR) of 0.69. With
these assumptions, 319 deaths among patients with
DLL3-high tumors were needed to achieve a 90% po-
wer on the basis of a log-rank test at a one-sided sig-
nificance level of 0.0225. Assuming a 19-month accrual
period and the last enrolled patient followed for 12
months, at least 480 patients with DLL3-high tumors
were to be randomized (240 subjects in each arm). A
target size of 740 patients (including 480 patients with
DLL3-high tumors) was estimated, assuming an
approximate prevalence of 65% for patients with
DLL3-high tumors.Because the study was terminated early as a result of
OS-based futility analysis, CRAC evaluation of PFS was
not performed. As a result, investigator-assessed PFS,
ORR, CBR, and DOR, which are exploratory study end
points, are reported here in a hypothesis-generating
manner.
Investigator-assessed PFS was defined from
randomization to disease progression as evaluated by
the investigator per RECIST v.1.1, or death of any cause,
whichever occurred first. OS was defined from
randomization to death of any cause. Median PFS and OS
were estimated using Kaplan-Meier method.
Investigator-assessed ORR was defined as the proportion
of patients with a best overall response (BOR) of CR or
PR per investigator assessment according to RECIST
v.1.1. CBR was defined as the proportion of patients with
a BOR of CR or PR or stable disease by investigator
assessment according to RECIST v.1.1. DOR was defined
from the day the patient met the criteria for confirmed
CR or PR per investigator assessment (whichever is
recorded first) to the date of progressive disease or
death, whichever comes first.
An unblinded interim analysis was conducted and
reviewed by the Independent Data Monitoring Commit-
tee. A futility analysis was planned when approximately
160 deaths in patients with DLL3-high ES-SCLC
(approximately 50% of the planned deaths) were
observed. If the estimated Cox HR for OS analysis of
Rova-T to placebo exceeded 0.9, the trial would be
stopped early.
The safety of Rova-T was evaluated through study
drug exposure and adverse events assessed by NCI
CTCAE version 4.0 until 70 days after the last dose of the
study drug.Results
Patient Characteristics and Disposition
A total of 1084 patients were screened between
February 7, 2017, and July 29, 2019. Of the 748 patients
enrolled, 372 patients were randomized to the Rova-T
arm and 376 patients to the placebo arm (Fig. 1). De-
mographics and baseline characteristics were well
balanced between the two arms (Table 1). The median
age was 64 years (range: 38–94), 581 (78%) of patients
had TNM stage IV disease, and 40 (5%) had stage IIIB
disease at the start of first-line therapy. Of the 748
randomized patients, 457 (61%) had DLL3-high
expression. On completion of four cycles of first-line
platinum-based chemotherapy, 581 patients (78%) had
a BOR of CR or PR and 167 (22%) had a BOR of stable
disease per RECIST v.1.1 criteria as assessed by inves-
tigator. History of CNS metastases was documented in
110 (15%) of patients at baseline. Of the 320 patients
1084 Screened for enrollment
(457 DLL3-high subset)a
336 Excluded
376 (240)a Randomized to 
placebo
741 (450) Included in safety 
analyses
373 (237) Received ≥1 dose
376 (240) Discontinued study
  • 201 (135) Death
  • 163 (100) Study terminated by sponsor 
  • 7 (3) Withdrawal by patient
  • 2 (1) Lost to follow-up
  • 3 (1) Other
372 (217) Discontinued study
  • 226 (131) Death
  • 134 (80) Study terminated by sponsor 
  • 7 (4) Withdrawal by patient
  • 3 (2) Lost to follow-up
  • 2 (0) Other
368 (213) Received ≥1 dose
3 Did not receive 
study drug
748 (457) Included in 
efficacy analyses 4 Did not receive 
study drug
372 (217) Randomized to 
Rova-T
Figure 1. CONSORT diagram for all randomized patients in the MERU study. aNumbers in parentheses denote number of
patients in the DLL3-high subset (75% DLL3-positive tumor cells using a rabbit anti-DLL3 antibody). Rova-T, rovalpituzumab
tesirine.
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arm without previous history of CNS metastases, PCI was
administered to 72 patients (23%) and 73 patients
(23%), respectively, before randomization (Table 1).
At the data cutoff date of February 19, 2019, the
median time on the study was 8 months (range: 0.1–
25.6). The median time from the last dose of platinum-
based chemotherapy to randomization was 6.3 weeks
for the placebo arm and 6.1 weeks for the Rova-T arm.
The median time from initial diagnosis of ES-SCLC to
randomization was 20.6 weeks for both Rova-T and
placebo arms. A total of 156 patients (42%) in the
Rova-T arm and 107 patients (29%) in the placebo
arm had completed two cycles of study drug admin-
istration, and 127 (35%) and 225 (60%) of patients in
the Rova-T and placebo arms, respectively, had
completed one cycle of study drug administration. The
median time on Rova-T was 18 weeks (range: 6.0–
80.0), and the median time on placebo was 6 weeks
(6.0–109.1).
All randomized patients had discontinued the study
as of February 19, 2020. The primary reasons for
study discontinuation in the Rova-T arm included death
(n ¼ 226; 61%), study termination by sponsor (n ¼ 134,
36%), withdrawal by patient (n ¼ 7; 2%), lost to
follow-up (n ¼ 3; 1%), and other reasons (n ¼ 2; 1%).
In the placebo arm, the primary reasons for study
discontinuation were death (n ¼ 201; 53%), study
termination by sponsor (n ¼ 163, 43%), withdrawal
by patient (n ¼ 7; 2%), lost to follow-up (n ¼ 2; 1%),
and others (n ¼ 3, 1%).Efficacy
Efficacy analyses were performed in the randomized
set and in the DLL3-high subset. There were 131 deaths
(60%) in the Rova-T arm and 135 deaths (56%) in the
placebo arm of the DLL3-high subset. Per protocol
specifications, a futility analysis was performed after
approximately 50% of the expected deaths in the DLL3-
high patients. For this subset, the median OS was 8.5
months (95% confidence interval [CI]: 7.3–10.2) in the
Rova-T arm and 9.8 months (95% CI: 8.4–10.9) in the
placebo arm (stratified log-rank p value ¼ 0.537), with
6-month OS rates of 70% and 66%, respectively
(Fig. 2A). Using a Cox proportional hazards model,
adjusting for randomization stratification factors, the HR
for OS was 1.07 (95% CI: 0.84–1.36), favoring the pla-
cebo arm; hence, the futility criteria were met. As the
study was terminated after the lack of OS benefit in fu-
tility analysis, PFS evaluation by CRAC was not con-
ducted, and only the exploratory end point of PFS by
investigator assessment is reported here. As assessed by
investigator, the median PFS for the DLL3-high subset
was 4 months (95% CI: 3.2–4.1) in the Rova-T arm and
1.4 months (95% CI: 1.4–1.5) in the placebo arm (HR
0.48, 95% CI: 0.39-0.59) (Fig. 2B). In the DLL3-high
subset, 189 patients in the Rova-T arm and 214 pa-
tients in the placebo arm were evaluated for response;
the investigator-assessed ORR was 10% and the CBR
was 72% in the Rova-T arm versus an ORR of 5% and
CBR of 30% in the placebo arm. Response rates and DOR
for randomized and DLL3-high patients are summarized
in Supplementary Table 1.






Median age (range), y 64 (38–85) 64 (39–94)
Male, n (%) 239 (64) 258 (69)
ECOG PS, n (%)
0 149 (40) 146 (39)
1 224 (60) 222(60)
Missing 3 (1) 4 (1)
TNM stage at start of first-line
therapy, n (%)
IA 1 (0.3)a 0
IB 0 0
IIA 0 0
IIB 0 1 (0.3)b
IIIA 4 (1) 3 (1)
IIIB 16 (4) 24 (7)
IV 295 (78) 286 (77)
Missing 60 (16) 58 (16)
Response to platinum, n (%)
Stable disease 84 (22) 83 (22)
PR or CR 292 (78) 289 (78)
Lactate dehydrogenase, n (%)
>ULN 90 (24) 89 (24)
ULN 265 (71) 269 (72)
Missing 21 (6) 14 (4)
History of brain
metastases, n (%)
Yes 56 (15) 54 (15)
No 320 (85) 318 (85)
Previous PCI, n (%)c
Yes 72 (23) 73 (23)
No 247 (77) 244 (77)
Missing 1 (0.3) 1 (0.3)
DLL3 status, n (%)
High (75%)d 240 (64) 217 (58)
Low (0% to <75%) 120 (32) 148 (40)
Not evaluated (
DLL3 status unknown)
16 (4) 7 (2)
aOne patient in the Rova-Tarm had TNM stage IIB disease at start of first-line
therapy and progressed during or after first-line therapy before study entry
(protocol deviation).
bOne patient in the placebo arm had TNM stage IA at initial diagnosis in 2007
and subsequently progressed or showed recurrence after initial treatment
and before initiation of first-line therapy for extensive disease (TNM stage
not reported/not applicable).
cPrevious PCI was only offered in patients with no history of brain metastases
if permitted by institutional guidelines; percentages are calculated out of
number of patients with no history of brain metastases.
dHigh DLL3 expression was defined as having greater than or equal to 75%
tumor cells staining positive according to the Ventana DLL3 (SP347) immu-
nohistochemical assay.
CR, complete response; ECOG, Eastern Cooperative Oncology Group; PR,
partial response; PCI, prophylactic cranial irradiation; PS, performance
status; Rova-T, rovalpituzumab tesirine; ULN, upper limit of normal.
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ondary end point) was 8.8 months (95% CI: 7.95–9.53)
in the Rova-T arm and 9.9 months (95% CI: 8.6–11.0)
in the placebo arm (95% CI: 0.92–1.36, HR ¼ 1.12,
p ¼ 0.237). The median PFS as evaluated by
the investigator (exploratory end point) for therandomized set was 3.7 months (95% CI: 2.9–4.0) in
the Rova-T arm and 1.4 months (95% CI: 1.4–1.5)
in the placebo arm (95% CI: 0.44–0.60, HR ¼ 0.51).
The investigator-assessed ORR for all randomized
patients was 9% (28 of 318) in the Rova-T arm and 4%
(14 of 330) in the placebo arm. Furthermore, the
investigator-assessed CBR was 66% (211 of 318) in
the Rova-T arm and 34% (112 of 330) in the placebo
arm (Supplementary Table 1).
Physical functioning was evaluated in the random-
ized set, as measured by the EORTC QLQ-C30 question-
naire (Table 2 and Supplementary Fig. 1). At baseline,
the mean EORTC QLQ-C30 score in the Rova-T and pla-
cebo arms was equivalent. At week 6 visit, the mean
EORTC QLQ-C30 score had slightly declined in both
arms. The mean EORTC QLQ-C30 score in the Rova-T
arm further declined from baseline at week 12, week
18, and week 24 visits, although no appreciable change
was observed at these time points in the placebo arm.
The least square mean difference between the two arms
at weeks 6, 12, 18, and 24 suggested more decline in
physical functioning in the Rova-T arm compared with
the placebo arm over time (Table 2 and Supplementary
Fig. 1).Subgroup Analysis of the Randomized Set
Analyses of OS and PFS (investigator-assessed) by
protocol-specified stratification factors are summarized
in Figure 3 and Supplementary Table 2. In the Rova-T
arm, patients with DLL3-low tumors (<75% DLL3-
positive cells) and patients with DLL3-high tumors
(75% DLL3-positive cells) did not have a marked dif-
ference in median OS (9.0 mo versus 8.5 mo). No dif-
ferences in outcome depending on DLL3 expression
were found in the placebo arm as well. No significant
improvement in median OS was observed with Rova-T
versus placebo for any of the subgroups (Fig. 3A).
Similar to the finding in the overall population, median
PFS as evaluated by the investigator (exploratory end
point) was markedly improved in the Rova-T arm
compared with the placebo arm in all subgroups
(Fig. 3B).Safety
Safety analysis was conducted in patients who
received at least one dose of Rova-T (n ¼ 368) or pla-
cebo (n ¼ 373). Overall, 343 (93%) patients in the Rova-
T arm and 304 (82%) in the placebo arm experienced at
least one treatment-emergent adverse event (TEAE). The
most common any-grade TEAEs in the Rova-T arm were
pleural effusion (27%), decreased appetite (27%), pe-
ripheral edema (26%), photosensitivity reaction (25%),
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Figure 2. (A) OS and (B) PFS by investigator assessment (DLL3-high subset). CI, confidence interval; OS, overall survival; PFS,
progression-free survival; Rova-T, rovalpituzumab tesirine.
1576 Johnson et al Journal of Thoracic Oncology Vol. 16 No. 9most common any-grade TEAEs in the placebo arm were
fatigue (16%), nausea (14%), and decreased appetite
(13%) (Table 3). Grade greater than or equal to 3 TEAEs
occurred in 217 patients (59%) in the Rova-T arm and
111 (30%) in the placebo arm, with the most common
grade greater than or equal to 3 TEAE (excluding ma-
lignant neoplasm progression) being thrombocytopenia
(9%) with Rova-T and hyponatremia with placebo (5%).
Serious TEAEs were reported in 157 patients (43%) in
the Rova-T arm and in 87 patients (23%) in the placebo
arm. Serious TEAEs occurring in greater than 2% of
patients in both treatment arms are summarized in
Supplementary Table 3.
Overall, 290 patients (79%) and 145 patients (39%)
experienced TEAEs possibly related to the study drugin the Rova-T and placebo arms, respectively. Common
possible study drug-related TEAEs in the Rova-T arm
included photosensitivity reaction (24%), peripheral
edema (22%), pleural effusion (20%), fatigue (18%),
thrombocytopenia (17%), decreased appetite (16%),
pericardial effusion (14%), nausea (13%), increased
aspartate aminotransferase (10%), face edema (10%),
and dyspnea (10%). Common TEAEs possibly related
to the study drug in the placebo arm were fatigue
(9%), nausea (6%), peripheral edema (5%), and
decreased appetite (5%). The TEAEs of special interest
included cutaneous reaction, generalized edema,
pleural effusion, pericardial effusion, edema, photo-
sensitivity reaction, pneumonitis, hypoalbuminemia,

































































































































































































































































































































































































































































































































































































September 2021 Rova-T Maintenance Therapy for ES-SCLC 1577frequency in the Rova-T arm compared with the pla-
cebo arm (Supplementary Table 4).
TEAEs led to death in 35 patients (10%) in the Rova-
T arm and 37 patients (10%) in the placebo arm, with
malignant neoplasm progression being the most com-
mon AE causing death in both arms (4% in Rova-T arm
and 5% in placebo arm). Other common causes of death
owing to TEAEs were pneumonitis, general physical
health deterioration, and sepsis in the Rova-T arm (n ¼ 3
each), and general physical health deterioration and
metastasis to the CNS (n ¼ 2 each) in the placebo arm.
Rova-T discontinuation owing to TEAEs was reported in
74 patients (20%), and placebo discontinuation owing to
TEAEs was reported in 26 patients (7%). TEAEs led to
Rova-T interruptions or delay in 63 patients (17%) and
placebo interruptions or delay in 12 patients (3%). A
total of 58 patients (16%) in the Rova-T arm and 5 pa-
tients (1%) in the placebo arm had dose reductions as a
result of TEAEs.Discussion
On the basis of the clinical activity and manageable
safety profile of Rova-T observed in previous phase 1 or
2 studies, MERU was the first phase 3 study designed to
evaluate the efficacy of Rova-T in a maintenance setting
after first-line platinum-based chemotherapy. Rova-T
failed to reveal OS benefit compared with placebo.
Further efficacy analysis by stratification factors
revealed similar overall trends, with shorter OS in the
Rova-T versus placebo arms. Because the OS futility
boundary was met during the futility analysis, the CRAC
review of PFS was not performed, and the primary
end point of PFS by CRAC and related secondary efficacy
end points were not evaluated. Thus, in addition to
OS, only preplanned exploratory efficacy end points of
PFS, ORR, DOR, and CBR by investigator assessment
are reported here. In line with the current MERU
study, a lack of marked improvement in survival has
been a common theme in several previous trials evalu-
ating maintenance therapy for ES-SCLC after platinum
chemotherapy.11,15–18
The ORR per RECIST v.1.1 criteria for the overall
randomized population was 9% with Rova-T and 5%
with placebo, and the CBR for the overall population
was higher with Rova-T versus placebo (66% versus
34%). Similar response rates were observed in the
DLL3-high patients. The lower ORR observed in
the Rova-T arm of MERU, as compared with other
Rova-T studies, is perhaps not unexpected in the
maintenance setting and could be attributed to the
ongoing response or disease control after four cycles of
platinum-based front-line chemotherapy administered
before randomization.
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Figure 3. Subgroup analysis of (A) OS and (B) PFS in prespecified subgroups (randomized set). A HR of less than 1 indicates a
lower risk of disease progression or relapse or death with Rova-T compared with placebo. The sizes of the circles are pro-
portional to the sizes of the subgroups, and the error bars denote 95% CIs. *Calculated using a Cox proportional hazard
regression model with treatment as covariate. CI, confidence interval; CNS, central nervous system; CR, complete response;
ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; LDH, lactate dehydrogenase; OS, overall survival; PCI, pro-
phylactic cranial irradiation; PFS, progression-free survival; PR, partial response; PS, performance status; Rova-T, rovalpi-
tuzumab tesirine; ULN, upper limit of normal.
1578 Johnson et al Journal of Thoracic Oncology Vol. 16 No. 9The incidence of grade greater than or equal to 3
TEAEs, drug-related AEs, and serious TEAEs was higher
in the Rova-T arm versus the placebo arm. Consistent
with previous phase 1 and phase 2 studies,9,10 Rova-T
was associated with a unique toxicity profile character-
ized by pleural and pericardial effusions, cutaneous re-
action, edema, photosensitivity reaction, pneumonitis,
hypoalbuminemia, and thrombocytopenia; these AEs of
special interest occurred at a much higher frequency in
the Rova-T arm compared with the placebo arm. The
unique toxicity profile of Rova-T has been attributed to
the PBD payload, with some of the characteristic toxic-
ities also observed with other PBD-based ADCs.19–21Previous Rova-T trials have described serosal effusions
and edema9,10,22 as particular hallmarks of Rova-T,
which were also observed in the present study.
Analysis of patient-reported outcome using the
EORTC QLQ-C30 questionnaire suggested a Rova-T–
induced decline in physical functioning, which was
observed in the Rova-T arm relative both to its baseline
and to the placebo arm at the same time points. The
decline in physical functioning over time along with
the toxicity profile of Rova-T suggests challenges with
Rova-T treatment in the MERU study. However, lower
doses of Rova-T used in other studies have revealed
better tolerability.23
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September 2021 Rova-T Maintenance Therapy for ES-SCLC 1579Because of the lack of survival benefit in the Rova-T
arm compared with the placebo arm at a preplanned
interim analysis, the MERU trial has been terminated per
the recommendation of the Independent Data Moni-
toring Committee.24 The phase 3 TAHOE study was also
terminated on the basis of the recommendation of the
Independent Data Monitoring Committee owing to a
shorter median OS observed in the Rova-T arm versus
the topotecan control arm.25 Because of these subopti-
mal results, the Rova-T research and development pro-
gram has been fully discontinued.24
In summary, Rova-T failed to improve OS in the
maintenance setting versus placebo in patients with ES-
SCLC. The primary end point of PFS assessment by CRAC
was not tested. The toxicities associated with Rova-T are
important risk factors to be considered during Rova-T
treatment. Although the development of Rova-T hasbeen terminated, safety and efficacy findings reported
herein highlight the need to carefully consider the
toxicity profile of novel therapeutics being tested in the
fragile population with ES-SCLC and may provide useful
insights for future studies in front-line maintenance after
platinum-based chemotherapy in ES-SCLC.Data Sharing Statement
AbbVie is committed to responsible data sharing
regarding the clinical trials we sponsor. This includes
access to anonymized, individual, and trial-level data
(analysis data sets), and other information (e.g., pro-
tocols and Clinical Study Reports), as long as the trials
are not part of an ongoing or planned regulatory sub-
mission. This includes requests for clinical trial data for
unlicensed products and indications. The clinical trial






Grades 1–2 Grade 3 Any Grade Grades 1–2 Grade 3 Any Grade
Any TEAE 126 (34) 217 (59) 343 (93) 193 (52) 111 (30) 304 (82)
Pleural effusion 83 (23) 15 (4) 98 (27) 11 (3) 2 (1) 13 (4)
Decreased appetite 92 (25) 6 (2) 98 (27) 48 (13) 2 (1) 50 (13)
Peripheral edema 91 (25) 4 (1) 95 (26) 28 (8) 0 28 (8)
Fatigue 84 (23) 9 (2) 93 (25) 59 (16) 1 (0.3) 60 (16)
Photosensitivity reaction 75 (20) 16 (4) 91 (25) 5 (1) 0 5 (1)
Nausea 76 (21) 4 (1) 80 (22) 49 (13) 2 (1) 51 (14)
Dyspnea 68 (19) 11 (3) 79 (21) 38 (10) 5 (1) 43 (12)
Thrombocytopenia 35 (10) 34 (9) 69 (19) 5 (1) 9 (2) 14 (4)
Pericardial effusion 58 (16) 4 (1) 62 (17) 7 (2) 1 (0.3) 8 (2)
Cough 53 (14) 3 (1) 56 (15) 43 (12) 1 (0.3) 44 (12)
Constipation 48 (13) 1 (0.3) 49 (13) 35 (9) 1 (0.3) 36 (10)
Increased aspartate aminotransferase 39 (11) 9 (2) 48 (13) 7 (2) 6 (2) 13 (4)
Increased alanine aminotransferase 30 (8) 9 (2) 39 (11) 7 (2) 1 (0.3) 8 (2)
Face edema 41 (11) 1 (0.3) 42 (11) 5 (1) 0 5 (1)
Vomiting 35 (10) 1 (0.3) 36 (10) 35 (9) 2 (1) 37 (10)
Asthenia 26 (7) 11 (3) 37 (10) 22 (6) 4 (1) 26 (7)
Diarrhea 30 (8) 0 30 (8) 34 (9) 2 (1) 36 (10)
Rova-T, rovalpituzumab tesirine; TEAE, treatment-emergent adverse event.
1580 Johnson et al Journal of Thoracic Oncology Vol. 16 No. 9data can be requested by any qualified researchers who
engage in rigorous, independent scientific research and
will be provided after review and approval of a research
proposal and Statistical Analysis Plan and execution of a
Data Sharing Agreement. Data requests can be submitted
at any time, and the data will be accessible for 12
months, with possible extensions considered. For more
information on the process, or to submit a request, visit
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